Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Addex Therapeutics Q3 Sales $370.87K Down From $430.68K YoY; Net Loss $2.96M Versus $4.65M YoY

Author: Benzinga Newsdesk | November 29, 2023 02:19am

Addex Therapeutics (NASDAQ:ADXN) reported $370.87 thousand in sales this quarter. This is a 13.89 percent decrease over sales of $430.68 thousand the same period last year.

Cash and cash equivalents decreased to CHF 4.8 million at September 30, 2023, compared to CHF 10.4 million at September 30, 2022.

Posted In: ADXN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist